Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/3/2025

Melatonin Therapy Guidelines

Indications and Dosage

  • The American Academy of Sleep Medicine suggests melatonin for adults with delayed sleep-wake phase disorder (DSWPD), with or without depression (weak recommendation) 3
  • For adults with DSWPD, dosing is 3-5 mg taken between 19:00-21:00 for at least 28 days 4
  • The American Academy of Sleep Medicine recommends weight-based dosing of 0.15 mg/kg administered 1.5-2.0 hours before habitual bedtime for children with DSWPD without comorbidities 1, 4
  • High-quality evidence shows reduction in initial sleep latency by 38-44 minutes in children with DSWPD without comorbidities 1
  • For children with DSWPD and psychiatric comorbidities, fast-release melatonin at 3 mg if <40 kg or 5 mg if >40 kg is recommended, administered at 18:00-19:00 for 4 weeks 1, 4
  • The American Academy of Sleep Medicine suggests melatonin for non-24-hour sleep-wake rhythm disorder in blind individuals, but the evidence is not explicitly stated in the provided text 1, 2
  • For REM sleep behavior disorder, dosing ranges from 3-12 mg at bedtime 5, 4

Conditions Where Melatonin is NOT Indicated

  • The American Academy of Sleep Medicine suggests against using melatonin for primary insomnia in adults (weak recommendation) 4, 3
  • Meta-analyses show only minimal effects on sleep onset, maintenance, or quality for primary insomnia in adults 4
  • The American Academy of Sleep Medicine suggests clinicians avoid melatonin for irregular sleep-wake rhythm disorder (ISWRD) in older people with dementia (weak recommendation against) 2
  • Evidence shows no improvement in total sleep time for ISWRD in elderly with dementia 2

Dosing Algorithm by Indication

  • Start with the lowest effective dose: 3 mg immediate-release for adults with DSWPD, titrate in 3 mg increments if needed (maximum 15 mg) 5, 4
  • For children with DSWPD without comorbidities, dosing is 0.15 mg/kg taken 1.5-2 hours before bedtime 1, 4
  • For children with DSWPD and psychiatric comorbidities, dosing is 3 mg (<40 kg) or 5 mg (>40 kg) 1, 4

Critical Safety Considerations

  • Use with caution in patients taking warfarin due to potential interactions 5, 4, 3
  • Use with caution in patients with epilepsy 5, 4, 3
  • Avoid in elderly patients with dementia and ISWRD 2, 5
  • Common adverse effects include daytime sleepiness, headache, and other sleep-related effects 3
  • No serious adverse reactions documented across all age groups when used at appropriate doses 5, 4

Important Clinical Caveats

  • Immediate-release formulations are more effective than slow-release for sleep onset 4
  • Choose United States Pharmacopeial Convention Verified formulations for reliable dosing 5, 4
  • Lower doses may be more effective, as higher doses may cause receptor desensitization or saturation 5
  • Long-term safety data beyond several months is limited, and the American Academy of Sleep Medicine recommends against long-term use for chronic insomnia due to insufficient safety and efficacy data 5